No Data
No Data
Coya Shares Rise After Next Step to New Study of ALS Treatment
Express News | Coya Therapeutics : Got Notification From FDA Stating That Additional Non-Clinical Data Is Required Prior to Initiation of Coya 302 ALS Study
Express News | Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute Along With Funding From the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform Into the Clinic
Express News | Coya Therapeutics Inc Files for Shelf of up to 603,136 Shares of Common Stock by Selling Stockholder - SEC Filing
Rodman & Renshaw Initiates Coverage On Coya Therapeutics With Buy Rating, Announces Price Target of $18
Rodman & Renshaw Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18
Rodman & Renshaw analyst Elemer Piros maintains $Coya Therapeutics(COYA.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 37.3
No Data